Prominent physicians from the World Professional Association for Transgender Health (WPATH) have finally admitted what many have suspected all along: puberty blockers are far more invasive than the media portrays, with irreversible effects that can significantly impact minors. These revelations came to light in WPATH’s educational sessions, exposing the harsh reality of these treatments.
Dr. Daniel Metzger, a pediatric endocrinologist and WPATH certified, shockingly revealed how puberty blockers prevent adolescents from developing essential calcium stores, crucial for preventing osteoporosis in later life. He equated puberty to a time of “filling the calcium piggy bank,” highlighting how blockers significantly slow down this critical process. By age 22, these individuals have not caught up, leaving them at risk.
Furthermore, the impact of puberty suppression on brain development in adolescents is still largely unknown. Metzger pointed out the rewiring and unwiring of teenage brains, raising concerns about how altering puberty affects cognitive functions like IQ and learning abilities.
Metzger also warned of the dire consequences for boys who start puberty blockers too early, as it hinders the development of genital tissue needed for future sex reassignment surgeries. This stark admission contradicts the often-repeated narrative of the harmlessness and reversibility of these treatments.
During a Q&A, Metzger discussed the severe impact on fertility, explaining how puberty blockers stop sperm development in males. The uncertainty surrounding whether girls who start blockers early can preserve mature enough eggs for fertility is alarming.
WPATH’s clinical guidance, which recklessly recommends starting puberty blockers at the onset of puberty, as young as age 8, has been called into question. Dr. Scott Leibowitz, a co-lead in the development of WPATH’s adolescent care standards, even criticized the often-touted “reversibility” of puberty suppression. He argued that it’s more invasive than portrayed, emphasizing the body’s need for sex hormones for critical development during puberty.
Leibowitz’s remarks about the challenges of puberty suppression and its long-term implications are particularly concerning. He highlighted the physiological necessity of binary sex hormones and the limitations of being on puberty suppression indefinitely, noting the significant asterisk attached to the term “reversible.”
What’s more alarming is Leibowitz’s stance on evidence-based medical care. He suggests that clinicians should not solely rely on medical evidence but also consider ethical aspects, like the rights and justice for transgender people. This stance dangerously prioritizes ideology over the well-being of vulnerable children and adolescents.
The admissions by these WPATH physicians expose the recklessness of the current approach to treating gender dysphoria in minors. It’s a wake-up call to the medical community and society at large. We’re talking about irreversible decisions impacting young lives, decisions that can lead to infertility, bone loss, and unknown effects on brain development.
